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Differential Screening of Phage-Ab Libraries by
Oligonucleotide Microarray Technology
Paolo Monaci1.*, Alessandra Luzzago1., Claudia Santini1, Alessandra De Pra1, Mirko Arcuri1, Francesca Magistri1, Alessandro Bellini1, Helenia
Ansuini1, Maria Ambrosio2, Virginia Ammendola2, Maria Giulia Bigotti1,2, Agostino Cirillo1, Maurizio Nuzzo1, Annamaria Assunta Nasti2, Philippe
Neuner1, Laura Orsatti1, Monica Pezzanera1, Andrea Sbardellati1, Giuseppe Silvestre1,2, Paolo Uva1, Valentina Viti1, Gaetano Barbato1, Stefano
Colloca1¤, Anna Demartis1, Emanuele De Rinaldis1, Saverio Giampaoli1, Armin Lahm1, Fabio Palombo1, Fabio Talamo1, Alessandra Vitelli1,
Alfredo Nicosia1¤, Riccardo Cortese1¤
1 Biotechnology Department, Istituto di Ricerca di Biologia Molecolare (IRBM) P. Angeletti, Pomezia, Rome, Italy, 2Centro di Ricerca per l’Ingegneria
Genetica (CEINGE), Napoli, Italy
A novel and efficient tagArray technology was developed that allows rapid identification of antibodies which bind to receptors
with a specific expression profile, in the absence of biological information. This method is based on the cloning of a specific, short
nucleotide sequence (tag) in the phagemid coding for each phage-displayed antibody fragment (phage-Ab) present in a library. In
order to set up and validate the method we identified about 10,000 different phage-Abs binding to receptors expressed in their
native form on the cell surface (10 kMembranome collection) and tagged each individual phage-Ab. The frequency of each phage-
Ab in a given population can at this point be inferred bymeasuring the frequency of its associated tag sequence through standard
DNA hybridization methods. Using tiny amounts of biological samples we identified phage-Abs binding to receptors preferentially
expressed on primary tumor cells rather than on cells obtained from matched normal tissues. These antibodies inhibited cell
proliferation in vitro and tumor development in vivo, thus representing therapeutic lead candidates.
Citation: Monaci P, Luzzago A, Santini C, De Pra A, Arcuri M, et al (2008) Differential Screening of Phage-Ab Libraries by Oligonucleotide Microarray
Technology. PLoS ONE 3(1): e1508. doi:10.1371/journal.pone.0001508
INTRODUCTION
In recent years monoclonal antibodies (mAbs) have proven to be
excellent therapeutic agents [1,2]. They have long half-life,
favorable pharmaco-kinetics in humans, none or very few adverse
reactions and a well established industry-scale production process
[1,3,4]. But their most significant feature is the ability to
specifically bind very diverse molecules with high affinity. Among
these, the receptors expressed on the surface of the eukaryotic cell
are particularly important as therapeutic targets. These receptors
mediate the response of the cell to environmental stimuli, and thus
it is not surprising that they play a key role in a large number of
diseases, including cancers, infections and auto-immune diseases
(e.g. Crohn’s disease, rheumatoid arthritis, asthma).
Therapeutic mAbs are generally selected following the identifica-
tion of a suitable target. Often, key information is provided by large
scale transcriptional studies which identify genes differentially
expressed in cells under normal and pathological conditions.
However this approach omits several potentially interesting targets,
such as those whose protein expression level does not vary in tandem
with the corresponding mRNA level, or those whose structure/
epitope is dependant on a post-translational protein modification, or
even those cases in which protein-protein interactions generate
novel, pathologically related epitopes. We therefore devised a highly
sensitive method to survey the differential binding of a large number
of clones which can be adapted to the very small scale of tissues
biopsies. This strategy allows the identification of epitopes with a
specific expression profile (e.g., tumor-specific), independently of any
biological information. The method is based on i) the availability of a
defined collection of phage-Abs binding to the epitopes of membrane
proteins (i.e. the Membranome collection) and ii) the possibility of
tagging every phage-Ab with a specific DNA tag sequence.
In silico analysis of the human genome predicts the total size of the
membrane protein (MP) coding genes-the Membranome–to be less
than 5,000. Thus, by using high throughput screening methods and
phage-displayed libraries, it is feasible to put together a collection
containing antibodies that bind to all or most MPs. Here we report
the creation of just such a large and diverse collection of Ab
fragments binding MPs, generated by panning phage-displayed
libraries of single-chain antibodies (scFv) on whole cells. Further-
more, we inserted a unique oligonucleotide tag sequence in each
phagemid of the Membranome collection, and generated two
populations by panning the tagged collection on tumor and on
normal tissue. Tumor-specific phage-Abs were identified by
comparing the frequency of each tag between the two populations.
This was quickly achieved by hybridizing the tag populations to a
customized tag-array microchip. The tumor-specific phage-Abs can
be used to identify their target and, after conversion into human
IgGs, for the phenotypic analysis of their biological properties.
RESULTS
Strategy for generating a collection of phage-Ab
binding Membranome proteins
We define as Membranome the ensemble of human genes coding for
proteins associated to the cell membrane. In silico analysis
identified about 4,600 genes populating the human Membranome
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(approx 20% of the human genome; see Materials and methods).
We built up a collection of phage-Ab that bind to the Membranome
proteins by high-throughput in vitro screening of naı¨ve phage-Ab
libraries, using various cell lines as ‘‘selectors’’. MPs expressed on
the cell surface maintain their native features: folding, post-
translation modification, expression of splicing variants and
formation of multimeric complexes. In addition, cultured cell
lines are reagents readily available with reproducible properties.
We analyzed in silico the variation in expression levels of MP-
encoding genes in a set of 25 cell lines (see Table S1). For each cell
line we ranked the MP-encoding genes according to their level of
gene expression. We considered genes expressed in a given cell line
when included in the top ranking expression level of 200, 300 or
400. This analysis reveals that about 30% of the MP-encoding
genes are expressed in only one of the 25 cell lines, whereas only a
small fraction (around 2–3%) are expressed in all the cell lines.
These data provide an estimate of the diversity of expression of the
MP- encoding genes across different cell lines. They also indicate
that increasing the number of cell lines generates a set expressing
as a whole an increasing number and eventually all the MP-
encoding genes.
Building up the Membranome phage-Ab repository
The workflow adopted to build up the Membranome phage-Ab
collection is schematically described in Figure 1. We used three
naı¨ve phage-Ab libraries derived from B cells of human healthy
donors which include over 1010 different clones each. [5]. These
libraries were panned separately on 64 different human cell lines
derived from 25 different tissues (see Table S2). We performed
only two rounds of panning to preserve the complexity of the
selected population of phage and limit the preferential amplifica-
tion of the most biologically viable clones. Phage-Abs from each
selected pool were individually screened by cell-ELISA for their
ability to bind the selector cell line. Positive clones with a novel
VH-CDR3 sequence were progressively added to the Membranome
phage-Ab collection. Automation of this process enabled high
throughput screening, and more than 112,000 clones were
analyzed by cell ELISA. Among these, about 40,000 clones
(41%) were confirmed positive and found to include 9,925
different VH-CDR3 sequences (8.8%). This set of 9,925 clones
is referred to as the 10k Membranome phage-Ab collection. On
average, 290 unique phage clones were selected from each cell line
and over 53% of these had a new VH-CD3 sequence. The
frequency (and also the number) of the new phage-Abs clones
derived from each cell line is steady, and not affected by the order
in which each cell line was used for selection. This strongly
suggests that this process, in addition to efficiently selecting a core
of antibodies that recognize common surface proteins, also selects
antibodies against target antigens over-expressed in a given cell
line, thus enhancing the repertoire of binding specificities included
in the collection.
Use of the Membranome phage-Ab collection
The 10 k Membranome phage-Ab collection is a ‘‘specialized’’, low-
complexity library of clones which bind receptors expressed in
their native form on the cell surface. This collection can be
surveyed to rapidly identify antibodies binding epitopes of known
cell-surface receptors. The most attractive use of the Membranome
collection, however, is to select antibodies targeting epitopes of
unknown receptors with specific expression features, which is the
case of the tumor-associated receptors specifically over-expressed
in tumor. Identifying such antibodies, however, is a goal barred by
the lack of an efficient protocol for differential screening. Let us
consider the case of a target and a reference biological sample.
Panning the Membranome phage-Ab collection on each of these
samples generated two phage populations. The goal is to identify
clones preferentially or exclusively present in one of the two
populations. Testing the binding specificity of individual clones
from these populations would require large quantities of biological
samples, which generally are available only in limited quantities,
and would survey only a minor part of the population.
We addressed the problem from a different perspective.
Sequencing a number of clones from the test and the reference
population of phage-Ab could reveal clones which are differen-
tially represented in the two pools, but clearly, a statistically
significant comparison of the two populations would require a very
large number of sequences. To efficiently acquire this information
we developed a novel DNA-based screening technology we called
tagArray. First we designed a set of short oligonucleotides that could
be used as tags and cloned each single tag into each phagemid
coding for a phage-Ab (see Materials and methods for details). In
this way we generated an association between a specific tag and a
specific scFv sequence, which makes it possible to measure the
frequency of each scFv clone in a population by measuring
frequency of the associated tag. Moreover, standard phage-
binding screening protocols can be replaced by well-established
DNA amplification and hybridization methods and high-through-
put technologies, such as DNA microarray. The tagArray
technology enables the entire populations to be compared in an
efficient and sensitive way, using minimal amounts of selector
Figure 1. Strategy adopted to generate the 10k Membranome
phage-Ab collection
doi:10.1371/journal.pone.0001508.g001
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samples. The screening protocol is organized in four steps: i) the
tagged phage population is panned in parallel on a biological and
a reference sample generating two distinct phage populations; ii)
tag sequences are amplified from the target and reference phage
populations, labeled with different fluorochromes and hybridized
on a double channel DNA microarray containing the complete
repertoire of tag sequences; iii) analysis of the hybridization data
identifies the tags differentially represented in the two populations;
iv) rescue of the scFv sequence associated to the relative tags are
rescued from the phage population (see Materials and methods).
Identification of phage-Abs that bind tumor cells by
tagArray screening
During the process of collecting the 10,000 phage-Ab of the 10 k-
Membranome collection, we generated a preliminary version
composed of the first 4,000 clones that were identified (4k-
Membranome phage-Ab collection). A set of tag sequences was
inserted in the phagemids of the 4k-Membranome collection, as
detailed in Materials and methods. Biopsy specimens from tumor
and adjacent normal tissues were collected from two colorectal
cancer (CRC) patients (pt#78 and pt#80), samples were
disaggregated by enzymatic treatment and the epithelial cells
affinity purified. The tagged 4 k Membranome collection was panned
on these primary epithelial cells to generate two pairs of tumor (T)
and normal (N) phage populations (T78 and N78; T80 and N80;
Figure 2). Tag sequences from each T and N matched population
were amplified, labeled with different fluorochromes, mixed and
hybridized to a DNA microarray containing the complete
repertoire of tag sequences. The intensity of the two fluorochromes
was measured for each spot of the microarray and analyzed as
average intensity and ratio from two independent fluor-reversal
experiments. The former reflects the average abundance whereas
the latter reveals the differential frequency of each tag in the
matched populations. Candidate tags were selected on the basis of
statistical criteria (see Materials and methods) limiting our analysis
to tags whose average intensity was higher than log210. Since we
aimed at identifying clones specifically enriched in the T as
compared to the matched N phage population, we focused our
attention on tags exhibiting the highest T/N ratio in both patients
(average T/N ratio higher than 70% of the maximal ratio detected
at the same intensity). This process identified a set of 174 tags
among which we randomly chose a subset of 61 elements. By
utilizing a nested PCR amplification protocol employing primers
encompassing the tag sequence, we recovered 45 different phage-
Abs associated with the selected tags from the T populations. This
partial redundancy in the phage-Abs identified was expected since,
under the experimental conditions adopted, a phage-Ab can be
associated to more than one tag.
Flow cytometry was used to measure the binding of three
phage-Abs to the primary cells from tumor and normal tissue
obtained from pt#78 and pt#80. As reported in Figure 3a, all
three phage-Abs differentially bound tumor cells, whereas the
matched normal cells and clone HL60-D3-232 retained its binding
specificity when formatted as IgG (Mbr-4; Figure 3b). It is worth
noting that the binding hierarchy measured by flow cytometry
matches that obtained by tagArray analysis.
Identification of target receptors
The phage-borne scFv identified as tumor-specific by tagArray
analysis were converted into human IgG1 format. Vectors
expressing the heavy and the light chains were co-transfected in
293-EBNA cells and the secreted IgGs were affinity purified from the
medium and immobilized on beads. Identification of antigens
targeted by these monoclonal antibodies (from now on referred to as
Mbr-#) followed the strategy illustrated in Figure 4. Membrane
proteins on living cells were selectively labeled with fluorescent dye
and solubilized in non-denaturing buffer. The proteins immune-
purified from this mixture by mAb-coated beads were then analyzed
by 1D-PAGE. Bands generated by specific binding of MPs were
identified by dual-wavelength scan, excised from the gel and digested
for Mass Spectrometry protein identification (see Materials and
methods for details). This biochemical approach identified the
transferrin receptor (TfRC) as the target of five different mAbs (Mbr-
2, 4, 43, 112 and 114). These results were confirmed by detecting a
specific binding of the same mAbs to CHO cell transfected with a
TfRC expression plasmid (data not shown).
Biological activity of selected IgGs
We characterized the binding of the mAbs to TfRC by surface
plasmon resonance. This analysis revealed KDs in the 5–140 nM
range with k-off values ranging from 2 to 40 msec21 for the
binding of IgGs to the soluble TfRC extra-cellular domain (see
Table S3). Apparent KDs between 3 and 12 nM on HCT-116 cells
were instead obtained using cell-ELISA. A molar excess of the
natural ligand transferrin inhibited binding of the five mAbs to
TfRC (data not shown).
Mbr-2, Mbr-4 and Mbr-114 inhibited cell proliferation in vitro in
6 cell lines at the concentration of 100 mg/mL (Figure 5a). Mbr-4,
the clone exhibiting the highest binding affinity for its target
receptor, was further characterized and shown to effectively
promote apoptosis of HCT-116 cells at concentrations ranging
from 0.8 to 20 mg/L (Figure 5b). Additional experiments indicated
that anti-proliferative and pro-apoptotic activities are exerted by
competition with transferrin for binding to TfRC (data not shown).
Mbr-4 in vivo anti-tumor activity was assessed by xenograft
experiment (Figure 6a and 6b). HCT-116 cells were injected
subcutaneously in BALB/c nude mice, immediately followed by an
intra peritoneal injection of Mbr-4 or an isotypic control. Both mAbs
were administered 3 times per week for 21 days and the percentage
of tumor-free mice and tumor growth monitored: The former
dramatically differed between the HCT-116 and BALB/c groups. At
day 11 measurable tumors were detected in all control mice (n = 12)
whereas only 1 tumor was observed in the group treated with Mbr-4
(n = 12; p,361025). On treatment end at day 21, only 2 mice had a
tumor in the Mbr-4 treated group. A significant difference between
the two groups was detected until day 64 when the experiment was
stopped. In line with these results, tumor volume was also lower in
the Mbr-4 treated group of mice than in controls.
DISCUSSION
In the majority of cases the identification of a therapeutic target
necessarily precedes the selection of a therapeutic mAb, whereas
we demonstrate that this ‘‘therapeutic target to mAb’’ approach
can be reversed. Here we describe a strategy which enables the
identification of antibodies that bind unknown receptors with a
specific expression profile. The first key stage of this strategy is the
selection of a relatively low-complexity, ‘‘specialized’’ library
containing phage-Abs that bind to MPs (the Membranome
collection). The second critical element is the development of a
technology that enables an efficient differential screening of phage
clones, using minimal amounts of biological samples.
We generated the Membranome collection by panning a phage-Ab
library on cultured cells This process simultaneously selects ligands
for several cell surface receptors. The complexity of the library, the
display level of the target receptor on the cell surface and the
affinity of the interaction between phage-Ab and the target
Membranome Repository
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receptor strongly affect this process. All these factors interact in a
competitive environment where biological viability of the phage-
Ab also plays a major role. Empirically, however, we observed that
on average the number of new clones identified by panning on
each different cell line remains relatively constant, indicating that
we are still far from saturation of the library sequence diversity.
The amino acid sequence of VH3-CDR3, the hypervariable
region which in most cases acts as a major binding determinant
[6–8], is a unique and distinctive feature of each member of the
repository. The Membranome phage-Ab collection hosts VH-CDR3
sequences ranging from 3 to 25 residues, with the frequency
peaking around 10 residues, and analysis of the complete scFv
region reveals a broad set of germline families. Together these two
findings indicate that a wide variety of binding motifs are present
in the collection. We estimate that the current version of the
repository (10,000 clones) should target between 500 and 1,000
different antigens, corresponding to 10–20% of the complete
Membranome. We also attempted to evaluate the diversity of
antigens targeted by the phage-Ab repository through two
independent approaches (see Text S1), and believe that a
Figure 2. Workflow of the tagArray screening procedure employed to identify tumor-specific phage-Abs.
doi:10.1371/journal.pone.0001508.g002
Membranome Repository
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conservative figure combining both approaches could be anything
between 10 and 20 clones per target. It is worth noting that the 18
target receptors identified so far are membrane proteins with one
or two trans-membrane domains and large (.700aa) extra-cellular
domains, along with several GPI-anchored membrane proteins.
The tagArray technology efficiently surveys the Membranome
collection and singles out clones which recognize receptor
molecules differentially expressed between two complex biological
systems of interest, achieved by coupling phage-display to high
throughput oligonucleotide microarray screening. To illustrate a
practical application of the Membranome phage-Ab collection, we
describe the identification of tumor-specific mAbs. An early
version of the collection which included 4,000 members was
surveyed for clones specifically binding epithelial cells from
primary colorectal tumors. This screening revealed that for each
patient, several phage-Abs specifically recognized primary cells
from tumor versus matched normal tissue although different
patients shared only a small fraction of these phage-Abs. A similar
finding has been reported for the screening of cDNA expression
clones from tumors using autologous or heterologous sera [9].
We focused our attention on the phage-Ab that specifically
reacted with tumor cells from two patients. Phage-Abs are good
binders and their interaction with the target molecule is efficiently
detected through the phage moiety. However, to perform
functional assays and to identify the target Ag, we converted the
selected phage-Ab into human IgG1. Using biochemical methods
combined with mass spectroscopy, TfRC, the main iron
transporter which binds and internalizes the iron carrier
transferrin, was identified as the target for six of these tumor
specific mAbs. Fast-paced tumor replication requires high levels of
iron uptake, thus TfRC is often over-expressed in breast, gastric,
colon cancer and glioblastoma [10] and has therefore prompted
the use of TRC as a target for anti-cancer therapy [11]. Some
examples are in a phase II clinical trial, transferrin fused to tetanus
toxoid protein showed 30% of responders in glioblastoma patients,
leading to the approval of a phase III trial [12]. In another study, a
mouse monoclonal was shown to induce apoptosis only in T
lymphocytes of acute T-cell leukemia patients, but not in PBMC
from healthy donors [13] and in line with this finding, an anti-
TfRC IgA showed clinical responses in lymphoma patients. More
recently, induction of apoptosis trough TfRC was reported using
Gambogic acid on a panel of cell lines [14].
tagArray technology is a versatile tool for profiling protein
expression on any cell surface. An increasing number of reports
show that, although closely related, transcriptional and proteomic
data do not always coincide [15]. Transcriptional profiling has a
further drawback of not detecting post-translational modifications or
variations in protein stability which also drive important biological
processes. Capitalizing on DNA-based technology, the Membranome
phage-Ab collection offers a complementary approach to standard
proteomic analysis by applying unmatched throughput and high
sensitivity of microarray technology to protein expression analysis.
This method provides a comprehensive multiplexed readout
(.20,000 data points) of the expression of receptors displayed on
the cell surface, and allows highly sensitive monitoring of their
variations. We anticipate that this technology will have a fundamental
impact on the identification of disease-associated biomarkers. This
same technology has the potential to provide novel information about
the biological mechanisms underlying several pathological conditions
and, at the same time, deliver useful reagents for validating
therapeutic hypotheses. We believe that the strategy and methods
described in this paper can be applied to other biological systems such
as the secretome, phosphoproteome, acetylome.
MATERIALS AND METHODS
In Silico identification of MP-coding genes
All protein coding genes within the NCBI Human Gene database
(26,651 genes) were analyzed using the NCBI Gene Ontology (GO)
annotation and the Phobius transmembrane segment and signal
peptide prediction algorithm [16]. A gene was classified as a
Figure 3. Binding specificity of selected clones. Binding of phage-Ab
HL60-D3-232, HeLa-D2-20, HL60-C3-16 and a control phage-Ab (a) or of
Mbr-4 and a control isotypic IgG (Mbr-ctrl; b) to human epithelial
primary cells was measured by flow cytometry. Primary cells were
obtained from matched tumor and adjacent normal tissue from CRC
patients #78 (white and dark grey bars, respectively) and #80 (pale
grey and black bars, respectively). Data are reported as percentage of
gated cells. In panel a, numbers on top of tumor sample bars refer to
the difference of percentage between that tumor and the matched
normal sample (top line) and to the T/N ratio detected by tagArray
analysis for the corresponding tags (bottom line).
doi:10.1371/journal.pone.0001508.g003
Membranome Repository
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Membrane Protein (MP) coding gene if either it was annotated as
localized in the ‘‘Plasma Membrane’’ according to the Gene
Ontology or one of the encoded peptides was predicted to be a
membrane protein by the Phobius algorithm. Approximately 26% of
the human genes were thus classified as MP genes and then subjected
to a semi-manual inspection to exclude proteins that are part of
intracellular compartments or the nucleus. Genes annotated to be
attached to the membrane by a GPI–anchor were manually extracted
from databases and added to the list. This left 4,609 MP genes,
approximately 19% of all genes (the human Membranome) as our target
gene population coding for cell surface antigens. In this analysis
additional complexity generated by alternative splicing events or post-
translational modifications were not taken into account.
MP genes expression analysis in cell lines
mRNA gene expression data from 25 cell lines (see Table S1) were
analyzed for variation of expression levels across the cell lines.
Expression levels were inferred using custom designed exon-
junction microarrays carrying multiple probes for each transcript
as described [17]. To estimate the reliability of absolute mRNA
quantification obtained by exon-junction microarrays, 40 genes
were independently assayed by TaqMan on the A549 cell line and
a good correlation was observed (data not shown). Transcript
abundance for about 3,700 MP genes represented on the exon-
junction chip was expressed as an interval of 100 to 60,000
arbitrary expression units. ‘‘Cell line surface diversity’’, here
defined as difference in composition of surface membrane
proteins, was estimated by the comparative analysis of the highest
expressed MP genes. For each cell line, MP genes were ranked
according to their expression values and those above an arbitrary
ranking threshold (rank ,= 200, 300 or 400) were selected as the
most abundant membrane proteins. This analysis revealed that a
considerable portion of the Membranome (about 30%) was expressed
at the highest level in only one out of the 25 cell lines, (see Table
S1). On the contrary, only a small fraction (around 2–3%) of MP
genes showed ubiquitous high expression levels across all cell lines.
Comparable results were obtained when, instead of the ranking
threshold, an absolute cutoff threshold was applied to expression
levels. Individual cell lines contributed to various degrees to the
fraction of cell-specific MP genes, with HUVEC and G361
contributing most. In order to obtain a global picture of the cell
line surface diversity, a clustering analysis was carried out. All
genes expressed above the ranking threshold (rank ,= 200, 300 or
400) in at least one cell line were selected and clustered
hierarchically (average link) using the euclidean distance measure.
Phage selection
Human, non-immunized scFv phage-displayed libraries were used as
source of binders. These are high complexity libraries (over 1010
different clones each) derived from B cells of healthy donors [5].
Each phage-Ab library (about 1011 TU) was independently panned
on 64 different cell lines (listed in Table S2). In each selection phage
libraries were incubated with MPBS (3% powdered non-fat dry milk
in PBS solution) for 30 min at room temperature (RT). Human cells
used in the selection were detached from the plate using 2.5 mM
EDTA in PBS and re-suspended to a final concentration of 16107
cells/mL. Following centrifugation, cells were re-suspended with
pre-adsorbed phage-Abs solution and incubated for 1 hour at RT.
After extensive washing with PBS, cell-bound phage were
centrifuged 5 min at 2 k rpm and re-suspended in 800 mL of trypsin
solution (1 mg/ml in sodium phosphate). E. Coli TG1 cells (New
England Biolabs, Beverly, MA) were infected with eluted phage and
plated on 2XTY agar containing 2% glucose and 100 mg/mL
ampicillin (2XTYAG). Phage rescue and amplification was carried
out as described [18]. The selected phage were panned again on the
same cell line. A variable number of clones (in the range 100–1,000)
were randomly chosen form the pool of selected phage and tested by
phage ELISA for their ability to bind the same cell line.
Whole-cell phage-ELISA
Cells were seeded overnight in 96 well plates at the concentration
of 46104 cells in 100 mL of propagation medium per well.
Following blocking with MPBS, phage supernatants were added to
each well and incubated for 1 hour at RT. After washing with
PBS, binding of phage antibodies was revealed with HRP-
conjugated anti-M13 antibody (Amersham Biosciences, Pittsburg,
PA) in MPBS, using tetramethylbenzidine (Sigma Aldrich,
Chicago, IL) as substrate. Phage-Abs whose binding to the target
Figure 4. Schematic outline of the biochemical strategy adopted for the identification of the target antigens. Membrane proteins on living cells
are selectively labeled with fluorescent dyes (i), then isolated in native conformation and in soluble form by extraction with appropriate buffers (ii).
The target antigen is pulled down using the beads-immobilized IgG of interest (iii). Immuno-purified material is analyzed by 1D-PAGE and membrane
proteins discriminated from non-specific binders by dual-wavelength scan of the gel (iv). Positive band is excised and processed for MS-based protein
identification.
doi:10.1371/journal.pone.0001508.g004
Membranome Repository
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cell line measured by A450nm-A620nm was at least three fold higher
than that observed with an unrelated phage and higher than 0.3
units were defined as positive.
tagArray repertoire
We identified 12 sequences sharing the following properties: i) 7
nucleotides long; ii) G2W5 base composition; iii) do not contain G-C
palindromes; iv) do not contain self complementary sequences; v)
have the same melting temperature, which is 10uC higher as
compared to each of the other 11 sequences. By combining 4 of these
building blocks we generated a repertoire of 20,736 (124) sequences
of 28 nucleotides. Each member of this repertoire has a 10uC
difference or higher in Tm with any other member of the repertoire.
Cloning the tag repertoire
Phagemid pCANTAB5 DNA was linearized by SapI restriction
and a synthetic dsDNA fragment with compatible cohesive ends
was inserted (AGCCTTAATTAATACGACTCACTATAGAG-
GCCTGGTACCCGGGTCGACTGTGTGTCT). The resulting
vector pCB5-PacI/XmaI has unique PacI and XmaI restriction
sites (underlined in the sequence above).
An oligonucleotide was synthesized by ‘‘mix and split’’
procedure which contained the complete (G2W5)4 sequence
repertoire flanked by constant regions (tagrep; CCTTAATTAA-
TACGACTCACTATAG(G2W5)4CCCGGGGG). An oligonu-
cleotide with sequence GGCCCGGG was annealed to tagrep
template and extended with DNA polymerase Klenov fragment.
The double-stranded DNA product thus generated was digested
with PacI and XmaI restriction enzymes and cloned into the
corresponding sites of pCB5-PacI/XmaI (pCB5-(G2W5)4 library).
By transformation in E.coli TG1 cells a number of colonies much
higher than the library complexity was obtained.
Tagging the 4k Mbr collection
The phagemid DNA derived from the 4k Membranome phage-Ab
collection was digested with SfiI and NotI restriction enzymes. The
Figure 5. In vitro characterization of anti-TfRC Mbr-4. (a) The indicated
cell lines were incubated for 72 hrs at 37uC with 100 mg/mL of Mbr-2,
Mbr-4, Mbr-114 or an isotypic control. Cell viability is reported as
percentage of the isotopic control treated cells. (b) HCT-116 cells were
incubated for 48, 72 and 96 hrs with 0.8 (N), 4 (&) and 20 (m) mg/mL of
Mbr-4 or with an isotypic control (#). Cell apoptosis is reported as
percentage of Annexin V-, 7AAD-positive cells.
doi:10.1371/journal.pone.0001508.g005
Figure 6. In vivo anti-tumoral activity of anti-TfRC Mbr-4. BALB/c
nude mice were challenged with a subcutaneous injection of HCT-116
cells at day = 0. A first group of mice (filled triangles; n = 12) was
administered with 10 i.p. injections of 0.5 mg IgG-4 three times a week
starting from day= 0. Mice from this group were followed up to
day = 64. A second group of mice (empty circles, n = 12) was
administered injections of control isotypic IgG according to the same
protocol and followed up to day = 35, when mice were sacrificed for
ethical reasons. Both groups were monitored for tumor growth
expressed as percentage of free mice (panel a) and tumor volume (b).
Error bars in panel b indicate standard error of the mean (S.E.M).
doi:10.1371/journal.pone.0001508.g006
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800bp fragment including the scFv sequences was purified and
cloned into the corresponding sites of the pCB5-(G2W5)4 library.
Upon transformation in E.coli, TG1 cells of about 10,000 colonies
were collected. Indeed, a computer-aided simulation indicated 2.5
times the scFv complexity as the best compromise between library
complexity and the association of multiple tags to the same scFv
sequence. A similar protocol was adopted to tag the 10k
Membranome phage-Ab collection.
Epithelial cell immunoaffinity purification
Tumor epithelial cells were purified using a protocol derived from
Buckhaults et al [19]. In brief, fresh dissected tissue was digested
with collagenase and DNase at 37uC in DMEM+ (DMEM, 1%
FCS, 20 mM HEPES, Penicillin-Streptomycin). The resulting
material was filtered through a nylon mesh to obtain single cell
suspensions. After red blood cells lysis, cells were immediately used
for panning or re-suspended in 10% DMSO/FBS and stored in
liquid N2. In either case, before use, Ep-CAM positive epithelial
cells were selected using autoMACS separator (Miltenyi Biotec,
Bergisch Gladbach, Germany) according to manufacturer’s
instruction, and tested for their via1bility using Guava Personal
Cytometer (Guava Technologies Inc., Hayward, CA).
tagArray screening
The tagged 4 k Mbr phage-Ab library was panned on primary
human epithelial cells derived from tumor or matched normal
samples as described above. Usually 107 cells were incubated with
1011 phage. Following extensive washing, cell-bound phage were
eluted and used to infect TG1 cells. The Ampicillin-resistant
bacterial colonies were collected and phagemid DNA purified by
DNA purification kit (Qiagen GmbH, Hilden, Germany). Tag
sequences were amplified by PCR. Forward primer was 59-
labelled with Cy5 or Cy3 dyes. Reaction mix included 30 ng
phagemid DNA, 5 mM labeled forward and reverse primers,
200 uM dNTPs and 2.5 units Taq polymerase (Promega, Madison,
WI) in a final 50 mL volume. Nine explicitly tagged-phagemids with
different relative ratios and absolute amounts were added to the
reaction. These ‘‘spike in’’ probes monitored whether the amplifi-
cation process maintained the original relative frequencies of the
clones in the amplified population. The amplification product was
first purified from salts, free primers and dNTPs by a commercially
available removal kit (Qiagen GmbH, Hilden, Germany). An aliquot
was then run onto an agarose gel and the Cy5- or Cy3-labeled
fragment was quantified by a fluorescence scanner (Typhoon; Perkin
Elmer, Waltham, MA).
The Hybridization mix was assembled in a 490 mL final volume
containing 3.5 mM Cy5- and Cy-3 labeled probes, 0.5 mM
blocker and reverse primer. The latter perfectly hybridizes to the
phagemid sequences flanking the tag, thus allowing the tag to
interact with complementary tag sequences immobilized on a
custom designed microArray chip (Agilent Technologies, Palo
Alto, CA). The reaction mix was incubated at 99.9uC for
2 minutes and then snap-cooled by transferring back in ice for
1 min. The mix was then applied onto tagArray_44 k chip and
incubated at 64uC for 15 hours in a rotating chamber. The slide
was then washed at RT in 6xSSPEL (66 SSPE, 0.005% N-
Lauroylsarcosine), 0.06xSSPEL, rinsed in stabilization and drying
solution (Agilent Technologies, Palo Alto, CA) and analyzed with
Agilent scanner. Images were acquired at 10mm resolution using
an Agilent scanner, with the XDR option enabled (eXtended
Dynamic Range: for each slide two images were generated with
photomultiplier tube voltages of 100 and 10, respectively). Images
were then processed using the Feature Extraction software (v 9.1,
Agilent Technologies, Palo Alto, CA) generating the net signal for
each channel (Cy3 and Cy5) and p-values after background and
dye-bias correction. Results reported were obtained by combining
data from two independent fluor reversal experiments.
Rescue scFv associated to selected tags
For each tag sequence we generated a primer including the two 59
blocks (X1X2) preceded by the adjacent 59-CGACTCACTATAG-
39 constant region (primer dynoX1X2) and a primer encompassing
the 4 blocks (primer X1X2X3X4). A reverse primer complemen-
tary to the phagemid region downstream of the scFv was used in
conjunction with the dynoX1X2primer in a PCR reaction using
the T phagemid DNA population as template. The product of this
first amplification was diluted and re-amplified using the primer
X1X2X3X4 and the reverse primer. The PCR products obtained
were sequenced and the corresponding 10k Membranome phage-Ab
clones identified.
scFv to IgG1 conversion
The scFv VH and VL sequences were introduced into a
mammalian expression plasmid to produce the IgG1 heavy or
light chain by using the GatewayTM technology (Invitrogen,
Carlsbad, CA). In our hands, the frequency of recombinant clones
was higher than 90% for both VH and VL insertion, close to the
efficiency reported for different vector systems based on Gateway
technology. The two plasmids secreting the IgG1 light and heavy
chains were co-transfected into 293-EBNA cells. Cell culture
medium was harvested every 3 days, samples collected together
and purified on protein A affinity column.
Target antigen identification
A-549, HCT-116 and MCF7 cells were grown at 70–80%
confluence and cell surface proteins labeled with Cy5 fluorescent
mono-reactive dye (Amersham, Uppsala, Sweden). About 20% of
the cells were washed with PBS and incubated for 30 minutes at 4Cu
in the presence of Cy5 dye (usually 1 vial of Cy5 dye/108 cells). The
Cy5 solution was removed and the cells washed with PBS. Cy5-
labeled and unlabeled cells were then incubated for 30 min at 4%C
in non-denaturing lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM
NaCl, 1% Triton-X100), complemented with Protease Inhibitors
cocktail (Amersham, Uppsala, Sweden) at a concentration of 106
cells/mL. The supernatant of Cy5-labeled and unlabeled cells was
then recovered, pooled and cleared by centrifugation. The native
membrane protein preparations (NMPs) thus generated were
immune-precipitated by incubation with a mAb covalently bound
to CNBr-activated sepharose beads (Amersham, Uppsala, Sweden)
at +4uC for 2hrs on a rotating wheel. The beads were then washed
with lysis buffer and the immune-precipitated proteins were eluted in
reducing loading buffer and analyzed by dual-wavelength 1D-PAGE
using a Typhoon 9410 (Amersham, Uppsala, Sweden). Protein
identification was performed essentially according to Shevchenko et
al. [20]. Briefly, the protein bands specific for membrane proteins
were excised and digested in-gel with modified porcine trypsin
(Promega, Madison,WI). Tryptic peptides were extracted from the
gel pieces, dried down, resuspended in 0.1% Trifluoracetic Acid and
desalted by mC18 ZipTip (Millipore, Bedford, MA). Peptides were
then analyzed either by Peptide Mass Fingerprint experiments
(MALDI-TOF-MS) using a Voyager DE sSTR (Applied Biosystems,
Foster City, CA) and the MASCOT software package or by capillary
LC-ESI-IT-MS/MS using a LCQ Deca XP Plus (Thermo,
Waltham, MA) equipped with a micro-electrospray source connect-
ed to a in-house packed C18 column (100 mm60.10 mm) and the
TurboSequest software (Xcorr values .2.5).
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Surface Plasmon Resonance
Sensorgrams were recorded on a Biacore 3000 instrument
operating at 25uC with CM5 chips (Biacore AB, Uppsala,
Sweden). The antibodies were immobilized using the unmodified
amine-coupling chemistry procedure suggested by Biacore.
Regeneration conditions were established for each antibody
according to the return of the baseline to the initial values.
Double referencing was used by subtracting the sensogram
resulting from an injection of running buffer. Mass transport
influence was minimized combining flow rate and low amount of
mAbs immobilized (ranging within 500–2000 RU). The titrations
to determine the kinetic constants of complex formation were
designed with 10 different analyte concentrations, plus one
duplicate concentration. All the titrations were performed in
duplicates with the kinject mode, using a flow rate of 50 mL/min
and a constant time (3 min). The data were analyzed with the Bia-
Evaluation 4.1 software using the Langmuir 1:1 binding model,
and the results are given as averages of the duplicates. When
feasible, the titrations were also performed at equilibrium. In this
case the flow rate used was 10 mL/min, with a contact time of
around 6 min. The equilibrium data were analyzed using the
equilibrium model within the Bia Evaluation software.
Flow cytometry
PEG-precipitated phage-Abs were re-suspended in PBBS (2% BSA in
PBS) and incubated for 30 min at RT. Primary human cells obtained
from tumor or normal tissue were incubated with phage-Ab solution
60min at 4uC (26105 cells with pre-blocked phage in 100 mL). After
washing with PBBS, cells were incubated with biotin-conjugated anti-
M13 phage monoclonal antibody (Progen Biotechnik, Heidelber,
Germany) for 30 min at +4uC. then washed and incubated with
streptavidin-APC (Molecular Probes/Invitrogen, Carlsbad, CA) or
with anti- Ep-CAM FITC Mab (Miltenyi Biotec, Bergisch Gladbach,
Germany) 30 min at 4uC. Finally, cells were washed and fixed with
1% PAF in PBS. mAbs were labeled by incubation with Zenon
Human IgG APC labeling kit (Molecular Probes/Invitrogen,
Carlsbad, CA) according to manufacturer’s guidelines. Target cells
were then incubated with pre-labeled mAb solution for 30 min at RT
(26105 cells in 100 mL of PBBS for 30 min). The same test was
performed by using the anti Ep-CAM FITC MAb (Miltenyi Biotec,
Bergisch Gladbach, Germany). In both cases cells were then washed
and fixed with 1% paraformaldehyde in PBS.
Mice
Mice were bred under specific pathogen-free conditions by Charles
River Breeding Laboratories (Calco, Como, Italy). In all manoeu-
vres, mice were treated in accordance with European guidelines. In
particular, at the time of injection mice were fully anesthetized with
ketamine (Merial Italia, Milano, Italy) at 100 mg/kg of body weight
and xylazine (BIO 98; Bologna, Italy) at 5.2 mg/kg.
Cell viability and apoptosis assays
HCT-116 cells were cultured in McCoy’s supplemented with 10%
fetal calf serum (FCS) in a humidified atmosphere with 5% CO2 at
37uC. For cell viability assays, cells were seeded in 96-well plates
(103 cells/well) and incubated for 72 hrs with 100 mg/mL of Mbr-
4 or an isotypic IgG used as negative control. Cell viability was
then measured using a fluorometric assay according to the
manufacturer’s instructions (Cell Titer Blue assay; Promega,
Madison, WI) and expressed as percentage of the value measured
by cells treated with the negative control. For cell apoptosis assays,
cells were seeded in 24-well plated (56103 cells/well) and
incubated for 48, 72 and 96 hrs with 0.8, 4 and 20 mg/mL,
respectively, of mAb-4 or an isotypic IgG as negative control. As
positive control 500nM apoptosis inducer Staurosporine was also
tested. Cell apoptosis was monitored by measuring Annexin V and
7-aminoactinomycin (7-AAD) expression using a Guava Personal
Cytometer (Guava Technologies Inc., Hayward, CA) and
expressed as percentage of the Annexin V-, AAD-positive cells.
No variation in the percentage of necrotic cells was detected. Data
were analyzed with one-way ANOVA (p,0.05).
In vivo experiments
BALB/c nude mice were challenged with a subcutaneous injection
of 46106 HCT-116 cells (day 0). The same animals were injected
with 0.5 mg of Mbr-4 or a control isotypic IgG at day 0, 2, 4, 7, 9,
11, 14, 16, 18, and 21 (12 animals per group). Mice were inspected
three times a week and tumor masses measured with calipers in
two perpendicular diameters. Growth was monitored until a
tumor exceeded an average diameter of 10mm, at which time
mice were euthanized for humane reasons. Data reported are
representative of two independent experiments.
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